Neurology & Brain Disorders Clinical Trials Update: Week 25, 2026

Published June 19, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study of Different Donanemab (LY3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (TRAILBLAZER-ALZ 6)

This Phase 3 trial explores new dosing schedules of donanemab, a treatment designed to reduce harmful brain changes in early Alzheimer's disease. By testing different ways to give this medication, the study aims to find options that work well while causing fewer side effects. Results from multiple countries, including the US and UK, are available and may offer hope for safer and more effective treatments in the future.

Aligning Medications With What Matters Most

This completed study looked at how a pharmacist-led review could help people living with dementia manage their many medications better. By simplifying medication routines, the goal was to reduce the burden and improve quality of life for both patients and their caregivers. Conducted in the United States, the findings support efforts to make treatment less complicated and more focused on what matters most to patients.

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

This Phase 2 trial is testing a combination of leuprolide acetate and standard Alzheimer’s drugs in women with Alzheimer’s disease or mild cognitive impairment. The hope is that this treatment will slow down memory loss and help maintain brain function longer. The study is active but not recruiting, and results are expected after nearly a year of treatment at sites in the United States.

Alzheimer's Disease THErapy With NEuroaid II

This Phase 3 study in Singapore is testing MLC901, a drug aimed at helping people with mild to moderate Alzheimer’s disease. If successful, it may provide a simpler treatment option to improve thinking and memory abilities. The trial is currently enrolling participants and could bring a new approach to managing Alzheimer’s symptoms.

Targeting Cognition in Early Alzheimer's Disease by Improving Sleep With Trazodone

This Phase 2 trial is exploring whether trazodone, a medication that helps improve sleep, can also benefit people with early memory problems linked to Alzheimer’s disease. Better sleep might support brain health and improve memory, offering a new way to manage early symptoms. The study is recruiting participants in the United States and plans to involve 100 people.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.